Controversies in the surveillance of patients with well differentiated thyroid cancer

Current Opinion in Oncology

Volumn 19, Issue 1, 2007, Pages 6-10

  Holt, Elizabeth ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18F FDG PET scan; Differentiated thyroid carcinoma; Thyroid cancer genetics

Indexed keywords

FLUORODEOXYGLUCOSE F 18; THYROGLOBULIN;

CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RESEARCH; DIAGNOSTIC VALUE; DISEASE COURSE; EVIDENCE BASED MEDICINE; HUMAN; MOLECULAR GENETICS; PATIENT CARE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TUMOR DIFFERENTIATION; UNITED STATES;

CELL DIFFERENTIATION; FLUORODEOXYGLUCOSE F18; HUMANS; POPULATION SURVEILLANCE; RADIOPHARMACEUTICALS; THYROID NEOPLASMS;

EID: 33845360825     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328011a24c     Document Type: Review

References (24)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. J Am Med Assoc 2006; 295:2164-2167.
2. Stat bite: Incidence of thyroid cancer by sex, 1975-2002. J Natl Cancer Inst 2005; 97:1722.
3. Grunwald F, Schomburg A, Bender H, et al. Fluorine-18-FDG and iodine-131 uptake in thyroid cancer. J Nucl Med 1996; 23:312-319.
4. Chin BB, Patel P, Cohade C, et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004; 89: 91-95.
5. 18F]fluorodeoxyglucose positron emission tomography in follow-up of differentiated thyroid cancer. Endocr Pract 2006; 12:152-158.
6. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006; 47:616-624. Well controlled study showing the increased accuracy of PET/CT fusion versus PET alone.
7. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91:498-505.
8. 131I-negative papillary thyroid carcinoma. Thyroid 2006; 16:267-272.
9. 18F] Fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase I expression in the primary tumor. J Clin Endocrinol Metab 2006; 90:328-334.
10. 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2005; 90:1440-1445.
11. Giovanella L, Ceriani L, Ghelfo A, Keller F. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med 2005; 43:843-847.
12. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin- stimulated serum thyroglobulin measurement predicts differentiated thyroid carcimoma metastases three to five years later. J Clin Endocrinol Metab 2005; 90:5047-5057.
13. Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004; 89:3402-3407.
14. Do Rosario PWS, Borges MAR, Fagundes TA, et al. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? Clin Endocrinol 2005; 62:121-125.
15. Schlumberger M. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? Clin Endocrinol 2005; 62:119-120.
16. Sherman SI, Angelos P, Ball DW, et al. Thyroid carcinoma. J Natl Compr Canc Netw 2005; 3:404-457. Annually updated guidelines for care of thyroid cancer patients.
17. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16:109-142. Very important published guidelines for clinical care. Detailed analysis of the quality of the data supporting each recommendation is provided.
18. Franklyn JA. Comparing USA and UK guidelines for the management of differentiated thyroid carcinoma. Thyroid 2006; 16:105-107.
19. Fagin JA. Editorial: challenging dogma in thyroid cancer molecular genetics - role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab 2004; 89:4264-4266.
20. Mitsutake N, Miyagishi M, Mitsutake S, et al. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinol 2006; 147:1014-1019.
21. Adeniran AJ, Zhu A, Gandhi M, et al. Correlation between genetic alterations and microsopic features, clinical manifestations, and prognostic characteristics of papillary thyroid carcinomas. Am J Surg Pathol 2006; 30:216-222.
22. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90:6373-6379. Large and thorough study of association between BRAF mutation and papillary thyroid cancer behavior.
23. Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumor aggressiveness. Virchows Arch 2005; 446:589-595.
24. - targeting to the membrane. Endocr Rel Ca 2006; 13:257-269.